Psilera

Psilocybin Drug By Psilera Could Treat Frontotemporal Dementia Without Psychoactive Effects

This Company's Psilocybin-Based Non Hallucinogenic Compound Heads Toward Clinical Studies

Another Win For Non-Hallucinogens: Meet Psilera's Candidates Poised For Clinical Stage Milestone

This Company's Psilocybin-Based Non Hallucinogenic Compound Heads Toward Clinical Studies

Another Win For Non-Hallucinogens: Meet Psilera's Candidates Poised For Clinical Stage Milestone

Iter Closes Last Funding Round Of Psychedelics Pool, Higher Capital Market Investment Than Expected

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold

Iter Closes Last Funding Round Of Psychedelics Pool, Higher Capital Market Investment Than Expected

|

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold

|

Can Psychedelics Reduce Alcohol Consumption? A New Study Looks Into It

|

Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies

|

Psilera Recent News

Biotech Co. Psilera Inc. Closes $2.5 Million Series A For Transdermal DMT Research

Florida-based Psilera Inc. has secured $2.5 million in funding for research, scientific and clinical personnel hiring and general working purposes. The company issued approximately 4.3 million shares to private buyers at a cost of $0.57 per share. Psilera has developed a patent-pending DMT transdermal patch to be assessed in a Phase 1b

|